Genetic disease involving the Human alpha glucosidase gene

Slides:



Advertisements
Similar presentations
Therapy of enzyme defects: general considerations ● How many organs are affected by the enzyme defect: One organ, a few, or all organs? ● How severe is.
Advertisements

Introduction to Medical Genetics Fadel A. Sharif.
Unit 4 Genetics Ch. 14 The Human Genome.
Chapter 6 The Proteins and Amino Acids Nutrition: Concepts & Controversies, 12e Sizer/Whitney.
Putting it all together: Finding the cystic fibrosis gene Cystic fibrosis (CF) is a genetic disorder that is relatively common in some ethnic groups A.
HEXA and Tay-Sachs Disease
DR. ERNEST K. ADJEI FRCPath. DEPARTMENT OF PATHOLOGY SMS-KATH
Introducing genes Genetics is the study of inherited traits and their variations. Genetics is not genealogy! Genealogy is the study of family relationships.
Chapter # - Chapter Title $100 $200 $300 $400 $500 $100$100$100 $200 $300 $400 $500 Human Heredity Human Chromosomes Human Molecular Genetics Human Heredity.
Unit 4 Vocabulary Review. Nucleic Acids Organic molecules that serve as the blueprint for proteins and, through the action of proteins, for all cellular.
TEMPLATE DESIGN © Genetic disease involving the Human alpha glucosidase gene Stephen Perritt, Ben Ernest, and Elizabeth.
The Lysosome and lysosomal storage disorders (LSD) Part III A Clinical profile of the LSDs Serge Melançon, MD February 2009.
WHAT IS GLYCOGEN STORAGE DISEASES (GSD) ?. - GSD has 2 classes of cause : (a) Genetic (b) Acquired.
Chapter 4: Cellular metabolism
Toll-Like Receptors in CNS Viral Infections Unclear role of TLRs in natural infections TLR3, -7, -8, -9 recognize viral nucleic acids. Localized intracellularly.
Molecular and Cellular Biochemistry 2. ER- protein modifications
Niemann-Pick Disease Maggie W. George December 5, 2005.
$Human Genome$. Human Genome Project & Goals It is an international effort to completely map and sequence the human genome, their are approximately 80,000.
Type 0 Type I Glycogen Storage Diseases Type IV Type VII Type III.
The Neurochemistry of Friedreich’s Ataxia By: Michelle Donnelly, Virginia Gamero, Vinson Li, and Pooja Maharajh PHM142 Fall 2015 Coordinator: Dr. Jeffrey.
Metabolism Dr. Samah Kotb Lecturer of Biochemistry 2015 Cellular Biochemistry and Metabolism (CLS 331)
Pompe’s Disease : Amino Acid Changes and Effects Support kindly provided by: Dept of BCMB; University of Tennessee, Knoxville Joel Bucci, Jennifer Ryan,
Glycogen Storage Diseases:
Yeast Lab 2 To do today: 1.Make lysates of WT, sec18 & sec61 strains grown at RT & 37°C. 2.Run lysates on 12% SDS- PAGE gel. 3.Score results from yeast.
1.Is NS-NPD caused by defect in a single gene or is more than one gene involved? Mutations in the NPC1, NPC2, and SMPD1 genes cause Niemann-Pick disease.
Regulation of Glycogen Metabolism
 Lysosomes (Greek words lysis, meaning "to separate", and soma, "body") are the cell's waste disposal system and can digest some compounds.  Lysosomes.
Rachel Wells. » Warren Tay, 1881 ˃Observed symptomatic red spot in retina of eye » Bernard Sachs, 1887 ˃Described cellular changes in disease ˃Noticed.
GENETIC BASIS OF DISEASE- part 2. Genetic basis of disease part 2 objectives a. Define inborn errors of metabolism b. Describe the common characteristic.
CELL ORGANELLES AND THEIR FUNCTIONS.
Chapter 18 – Gene Regulation Part 2
PEDIGREES.
Perturbations in desmin filament network formation in cells expressing a recombinant desmin protein harboring a 7-amino-acid deletion found in a patient.
Chapter 14: Human Heredity
Genetic Technology.
Insulin - A hormone from Pancreas Lecture NO : 02nd MBBS
Catabolism of amino acid nitrogen
Alglucosidase alfa (Approved drug) DB01272
Genomics A Systematic Study of the Locations, Functions and Interactions of Many Genes at Once.
Enzyme and gene therapy of enzyme defects
Infantile-onset GSDII
The Biochemistry of Life
Figure 1. Partial genetic and physical map of chromosome 5q
Genes and How They Work Chapter 15.
Glycogen Storage Diseases
Therapy of enzyme defects: general considerations
The Endomembrane system
Course in Molecular Biology
By Dr. Dipendra Raj Pandeya, PhD Assistant Professor Department of Clinical Laboratory Science College of Applied Medical Sciences Al Jouf University.
The Human Genome Chapter 14.
(3) Gene Expression Gene Expression (A) What is Gene Expression?
Clinical Genetics Lecture 4.
Section Objectives: Interpret a pedigree.
Glycogen Metabolism Clinical Chemistry Unit Department of Pathology
Different mode and types of inheritance
Volume 126, Issue 7, Pages (June 2004)
Volume 11, Issue 1, Pages (January 2005)
Chapter # - Chapter Title
Plant Biotechnology Lecture 2
wikispaces. com/file/view/cell_structure
DNA and the Genome Key Area 3a Gene Expression RNA.
Volume 25, Issue 5, Pages (May 2017)
Protein Synthesis DNA to Proteins.
Enzyme and gene therapy of enzyme defects
Glycogen Metabolism Clinical Chemistry Unit Department of Pathology
Volume 25, Issue 5, Pages (May 2017)
The Content of the Genome
Take 5 Which phase in meiosis do the tetrads break and are pulled to opposite poles of the cell? Which phase in meiosis do the chromosomes (paired chromatids)
The Human Genome Ch 14.
Analysis of protein-coding genetic variation in 60,706 humans
Presentation transcript:

Genetic disease involving the Human alpha glucosidase gene Stephen Perritt, Ben Ernest, and Elizabeth Johnson UTK and GST Funded by NIH, ISMD Award # 1R25GM086761-01 Mutations Pompe’s Disease Autosomal Resessive Genetic Disorder At present more than 200 different mutations in the acid α-glucosidase gene are known. The acid α-glucosidase gene (GAA) encodes a precursor protein of 952 amino acids with 7 N-linked carbohydrate chains. The first 37 N-terminal amino acids constitute a signal-peptide directing entry into the lysosomal / secretory pathway. The signal-peptide and an additional 19 amino acids are cleaved off before the precursor protein leaves the trans Golgi network (Moreland, et al., 2005; Wisselaar, et al., 1993). The apparent molecular mass of the intracellular (C) precursor is approximately 110 kD (C110). Transport from the trans Golgi network to the lysosomes is mannose 6-phosphate receptor mediated (Hasilik and Neufeld, 1980a; Hasilik and Neufeld, 1980b; Reuser, et al., 1985). Some newly formed acid α-glucosidase does not reach the lysosomes but is secreted into the culture medium (M) and has a similar molecular mass of approximately 110 kD (M110). The intra-cellular pool of precursor molecules is further modified by controlled proteolytic processing prior to or just after entry into the lysosomes. This results in the formation of larger 95 kD (C95), 76 kD (C76), 70 kD and smaller molecular species (< 20kD) (Hasilik and Neufeld, 1980b; Moreland, et al., 2005; Reuser, et al., 1985; Wisselaar, et al., 1993). The larger and smaller fragments are held together by S-S bridges, but are visible as separate species upon polyacrylamide gel electrophoresis under denaturing circumstances (SDS-PAGE) followed by Western blotting (Moreland, et al., 2005). The quantity and quality of these molecular species, as expressed in cells transfected with mutant compared to normal forms of recombinant human acid α-glucosidase cDNA and as visualized by amount and mobility in SDSPAGE, are in part informative for the severity of GAA sequence variations. The activity of acid α-glucosidase in these transfected cells provides more direct information on the functional effect of the mutation. Both types of assay were performed to analyze the impact of sequence variations. The enzyme deficiency in Pompe disease is caused by pathogenic mutations in the acid α-glucosidase gene (GAA) located on chromosome 17. The mode of inheritance is autosomal recessive. Autosomal recessive diseases follow the mode of inheritance described by the pedigree graphic below.   A patient has two pathogenic mutations in the acid α-glucosidase gene, one on each chromosome. Basically, the nature of the mutations in the acid α-glucosidase gene and the combination of mutant alleles determine the level of residual lysosomal acid α-glucosidase activity and primarily the clinical phenotype of Pompe disease. Although exceptional cases have been described, in general a combination of two alleles with fully deleterious mutations leads to virtual absence of acid α-glucosidase activity and to the severe classic infantile phenotype. A severe mutation in one allele and a milder mutation in the other result in a slower progressive phenotype with residual activity up to 23% of average control activity. In these patients genotype and enzyme activity are not always predictive of the age at onset and the progression of the disease. For example, patients with the common c.-32-13T>G mutation, combined with a fully deleterious mutation on the other allele, all show significant residual enzyme activity and a protracted course of disease, but onset of symptoms varied from the 1st year of life to late adulthood. Pompe disease, also termed glycogen storage disease type II or acid maltase deficiency, is an inherited lysosomal storage disorder with an estimated frequency of 1 in 40,000 births [1]. The disease is characterized by a total or partial deficiency of the enzyme acid α-glucosidase. This enzyme is needed to break down glycogen that is stored within the lysosome, a cytoplasmic organelle involved in cellular recycling and tissue remodeling. Deficiency of acid α-glucosidase leads to accumulation of lysosomal glycogen in virtually all cells of the body, but the effects are most notable in muscle. The pathologic mechanisms by which glycogen accumulation eventually causes muscle malfunction are not fully understood. Muscle wasting in Pompe disease has been explained by increased tissue breakdown by autolytic enzymes released from ruptured lysosomes [5]. Another hypothesis is that glycogen-filled lysosomes and clusters of non-contractile material disturb the myofibrillar morphology and thus the transmission of force in the muscle cells [6].   A novel mutation, C118t, in exon 2 of the acid -glucosidase gene has been found in an infant with glycogen storage disease type II. This mutation is predicted to result in protein truncation. The phenotype was that of the severe infantile form of the disorder with lack of motor development, but with eye regard, social smile and vocalization. Future Treatments Gene Therapy Chaperone References 1. Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 1999; 7:713-716. 2. De Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmans F. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem. J. 1955; 60:604-617. 3. Hers HG. a-Glucosidase deficiency in generalized glycogen storage disease (Pompe's disease). Biochem. J. 1963; 86:11-16. 4. Hirschhorn R, Reuser AJ. Glycogen storage disease type II; acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly W, Valle D (eds) The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001: p 3389-3420. 5. Umpleby AM, Wiles CM, Trend PS, et al. Protein turnover in acid maltase deficiency before and after treatment with a high protein diet. J Neurol Neurosurg Psychiatry 1987; 50:587-592. 6. Drost MR, Hesselink RP, Oomens CW, Van der Vusse GJ. Effects of non-contractile inclusions on mechanical performance of skeletal muscle. J Biomech 2005; 38:1035-1043.